Chimeric antigen receptor (CAR) T cell therapy relies on the ex vivo manipulation of patient
T cells to create potent, cancer-targeting therapies, shown to be capable of inducing …

In recent years, the development of nanoparticles has expanded into a broad range of
clinical applications. Nanoparticles have been developed to overcome the limitations of free …

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …

Nanomedicine has made significant advances in clinical applications since the late-20th
century, in part due to its distinct advantages in biocompatibility, potency, and novel therapeutic …

T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with
three approved products for B-cell malignancies and a large pipeline of treatments in clinical …

Cancer vaccines hold great promise for improved cancer treatment. However, endosomal
trapping and low immunogenicity of tumour antigens usually limit the efficiency of vaccination …

Advances in biomaterials for drug delivery are enabling significant progress in biology and
medicine. Multidisciplinary collaborations between physical scientists, engineers, biologists, …

The induction of a strong cytotoxic T cell response is an important prerequisite for successful
immunotherapy against many viral diseases and tumors. Nucleotide vaccines, including …

Clinical advances enable the prenatal diagnosis of genetic diseases that are candidates for
gene and enzyme therapies such as messenger RNA (mRNA)–mediated protein …

Recent years have witnessed incredible growth in RNA therapeutics, which has benefited
significantly from decades of research on lipid nanoparticles, specifically its key component—…